Abstract: Four different formats of bispecific antibodies (bsAbs) were generated that consist of anti-Her2 IgG or Fab site-specifically conjugated to anti-CD3 Fabu sing the genetically encoded noncanonical amino acid. These bsAbs varied in valency or in the presence or absence of an Fc domain. Different valencies did not significantly affect antitumor efficacy,w hereas the presence of an Fc domain enhanced cytotoxic activity,b ut triggered antigen-independent T-cell activation. We showt hat the bsAbs can efficiently redirect Tcells to kill all Her2 expressing cancer cells,i ncluding Her2 1 + cancers,both in vitro and in rodent xenograft models.This work increases our understanding of the structural features that affect bsAb activity,and underscores the potential of bsAbs as ap romising therapeutic option for breast cancer patients with low or heterogeneous Her2 expression.
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Human epidermal growth factor receptor 2(Her2) specific monoclonal antibodies,i ncluding trastuzumab and pertuzumab,a nd the recently approved antibody drug conjugate (ADC), trastuzumab emtansine (T-DM1), have markedly improved the prognosis for Her2-positive cancer patients. [1] [2] [3] However,aretrospective subgroup analysis of the clinical trials suggests that these agents are most effective in patients with Her2 overexpressing breast cancers (scored 3 + or 2 + by immunohistochemistry,I HC,a nd confirmed by fluorescence in situ hybridization, FISH), leaving as ignificant unmet medical need for patients with tumors that have low levels of Her2 expression (scored 1 + , % 30 %o fb reast cancer patients). [4, 5] Recently,T -cell-recruiting bispecific antibodies (bsAbs) that simultaneously bind tumor-associated antigens and an invariant component of the T-cell receptor (e.g., CD3 epsilon), have shown excellent clinical efficacy in the treatment of hematological malignances and various solid tumors. [6] Because the activation of Tcells by bsAbs does not rely on high copy numbers of the surface tumor antigen nor its intracellular trafficking, [7, 8] bsAbs may provide enhanced efficacy for cancer cells that express low levels of Her2, relative to ADC.I ndeed, potent efficacyo fH er2-targeted bsAbs has been previously demonstrated against tumor cells with low Her2 expression. [8, 9] Moreover,d ue to multiple cytotoxic mechanisms,Tcells engaged by bsAbs can potently target chemotherapy-resistant cancer cells and quiescent cancer stem cells. [10] [11] [12] However,t op revent severe side effects,s uch as cytokine release syndrome (CRS), [13] antigen-independentT -cell activation by bsAbs must be minimized.
Most current methods for the generation of bsAbs rely on genetic methods,s uch as the fusion of engineered antibody fragments (e.g., BiTE, DART,a nd Diabody) or the heterodimeric pairing of heavy chains (e.g.,T riomab and CrossMab). [14, 15] Previously,w er eported ag eneral method to synthesize bsAbs by genetically incorporating the noncanonical amino acid p-acetylphenylalanine (pAcF) into the Fab fragments of antibodies. [16] This method allows for conjugation of two distinct antibodies with control over the sites of conjugation and linker length in order to optimize immunological synapse formation. Herein, we further explore this approach by synthesizing several structurally distinct bsAbs and determining how variations in structure affect activity. BsAbs were constructed that bind Her2 and CD3 in either monovalent or bivalent mode,a nd either with or without af unctional Fc domain. We examined the effects of valency and the presence of an Fc domain on the in vitro cytotoxicity, pharmacokinetics,o ff-target toxicity,a nd in vivo efficacyo f these bsAbs using human breast tumors expressing different levels of Her2, and also compared the activity of these bsAbs to an anti-Her2 ADC consisting of trastuzumab conjugated with monomethyl auristatin F(T-nAF).
To vary valencya nd Fc receptor engagement by the bsAbs,w es ite-specifically incorporated pAcF into the antiHer2 antibody trastuzumab,a nd the anti-CD3 antibody UCHT1 at one [anti-Her2 IgG (HA121X), anti-Her2 Fab (LS202X), and anti-CD3 Fab( HK138X)] or two [anti-CD3 Fab( LS202X/HK138X)] distinct sites (where Xd esignates pAcF). All of the pAcF sites are located in constant regions of the antibodies,a nd were previously used for various sitespecific modifications without affecting the binding affinity of the molecules. [17, 18] Them utant Fabs were expressed in Escherichia coli (E. coli) [19] using an orthogonal M. jannaschii-derived tRNA/aminoacyl-tRNAs ynthetase (tRNA CUA / pAcFRS) pair that selectively incorporates pAcF into proteins in response to UAGw ith typical yields of 3-5 mg l À1 . TheI gG with pAcF was expressed in suspension CHO cells ( % 10 mg l À1 yield from transient transfection) with an E. coli-derived tRNA CUA /pAcFRS pair. [20] Next, the keto group of the mutant antibodies was site-specifically modified by forming an oxime linkage with bifunctional polyethylene glycol linkers containing an alkoxyamine on one terminus and an azide (anti-Her2 antibody) or cyclooctyne (anti-CD3 antibody) group on the other terminus ( Figure S1 in the Supporting Information, SI). Thec onjugation efficiency (> 90 %) was verified by ESI-MS (Table S1 ). This approach allows to couple the full length IgGs and Fabs in various formats using ac opper-free [3+ +2] Huisgen cycloaddition reaction ("Click" reaction). [21, 22] As showni nF igure 1A,w ed esigned four different IgGand Fab-based bsAbs that bind Her2 and CD3 in either am onovalent or bivalent mode:T etra-IgG (bivalent Her2 and CD3 binding), Tr i-IgG (bivalent Her2 and monovalent CD3 binding), Tr iFab (bivalent Her2 and monovalent CD3 binding), and BiFab (monovalent Her2 and CD3 binding). In addition, the IgG-based bsAbs (Tetra-IgG and Tr i-IgG) contain afunctional Fc domain, which may affect the overall efficacya nd selectivity of the constructs.E ach bsAb was synthesized by coupling the corresponding linker-modified antibodies at the appropriate concentration using ac opperfree Click reaction. Since IgG is homodimeric,t he modified anti-Her2 IgG (HA121X) has two reaction sites per molecule, and its reaction with excess anti-CD3 Fab( HK138X) yields Te tra-IgG.Onthe other hand, a1:1 molar ratio of the linkermodified anti-Her2 IgG (HA121X) and anti-CD3 Fab (LS202X/HK138X) leads predominantly to the formation of Tr i-IgG.T riFab was synthesized from the reaction of modified anti-CD3 Fab( LS202X/HK138X) with excess anti-Her2 Fab (LS202X). Lastly,BiFab was prepared by incubating an equal molar ratio of modified anti-Her2 Fab( LS202X) and anti-CD3 Fab(HK138X;SI). Following conjugation and purification by size exclusion chromatography,t he final yield was 50 %f or Te tra-IgG,2 5% for Tr i-IgG,3 0% for TriFab,a nd 75 %for BiFab.The molecular weight (Tetra-IgG, % 240 kDa; Tr i-IgG, % 193 kDa;T riFab, % 144 kDa;B iFab, % 100 kDa) and the purity (! 90 %) of each construct was confirmed by SDS-PAGEanalysis ( Figure 1B )and gel filtration (Superdex 200) analysis ( Figure S2 ). QTOF-MS analysis confirmed that all bsAbs were generated through covalent linkage of the desired chain (Table S2) .
Theb inding of each bsAb to its antigen was determined by flow cytometry analysis using human Tlymphocyte cells (Jurkat, CD3 +)a nd breast cancer cells (SKBR3, Her2 3 + ; MDAM B453, Her2 2 + ;M DA MB231, Her2 1 + ;M DA MB468, Her2 0). Theb reast cancer cell lines were chosen based on the reported Her2 expression levels that were determined by IHC and FISH, [23] [24] [25] and confirmed by flow cytometry analysis ( Figure S3 ). As shown in Figure 1C ,all of the conjugates bind both Her2-and CD3-expressing cells to as imilar extent (relative binding index of 1810 AE 217 to SKBR3, 673 AE 39 to MDAM B453, 18 AE 2t oM DA MB231, and 598 AE 50 to Jurkat;T able S3), which were comparable to the parental antibodies trastuzumab (relative binding index of 1519 to SKBR3, 626 to MDAM B456, 15 to MDAM B231) and UCHT1 (relative binding index of 410 to Jurkat). More importantly,all the bsAbs failed to bind to the Her2 0cancer cell, MDAM B468. Overall, these findings highlight an advantageous feature of the semisynthetic approach which largely preserves the binding activity and specificity of parental antibodies after conjugation.
To assess the ability of these bsAbs to selectively direct Tcells to Her2 expressing cancer cells,w ep erformed ac ytotoxicity assay using different Her2 expressing cancer cells [5, [23] [24] [25] [26] [27] [28] [29] in the presence of human PBMCs.A ss hown in Figures 2A and S4 , all bsAbs demonstrated excellent cytotoxicity against Her2-expressing cancer cells.Acomparison of the half maximal effective concentration (EC 50 )v alues indicates that these bsAbs have similar cytotoxicity against the target cells (Table S4 ). These results demonstrate that different binding valencies to target cells (TriFab versus BiFab) or Tcells (Tetra-IgG versus Tri-IgG) do not significantly affect the in vitro potencyo fb sAbs.T his may be attributable to the high affinity of the parental antibodies (trastuzumab K d = 0.1 nm [30] and UCHT1 K d = 1.6 nm [31] ), and/ or to as imilar degree of T-cell activation triggered by TCR 
Angewandte
Chemie crosslinking on the cell surface. [32] In addition, in comparison to Her2 3 + and Her2 2 + cells,all bsAbs demonstrated up to 100-fold increase of EC 50 and an approximate 30 %decrease of maximal killing with Her2 1 + cancer cells,w hich suggest that target cells with higher antigen densities can readily activate Tcells with lower concentrations of bsAbs.
Interestingly,a tc oncentrations greater than 100 pm,t he IgG-based bsAbs (Tetra-IgG and Tri-IgG) resulted in ahigher maximal killing in comparison to the Fab-based constructs (TriFab and BiFab) for Her2 3 + cancer cells (72.7 AE 2.6 % versus 56.8 AE 2.4 %f or SKBR3;6 8.3 AE 1.0 %v ersus 48.9 AE 0.5 %f or HCC1954;6 9.4 AE 1.8 %v ersus 53.6 AE 0.8 %f or MDAMB435/Her2). However, this improved cytolytic effect was not observed when these bsAbs are assayed using cancer cells with reduced Her2 expression (2 + and 1 +). This enhanced activity is likely ar esult of the presence of the Fc domain, which leads to the recruitment of Fc receptor (FcR)-bearing immune cells,asthis increase is not observed when purified Tcells are used ( Figure S5 , Table S5 ). Consistent with this notion, we found that trastuzumab induces Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) with these Her2 overexpressing breast cancer cells (Figures 2A and S4).
We next evaluated if different bsAb formats result in differing degrees of nonspecific T-cell activation which could result in potential off-target toxicity.A ss hown in Figures 2Band S6 , the IgG-based bsAbs (Tetra-IgG and Tr i-IgG), but not the Fab-based bsAbs,i nduced antigenindependent cytotoxic activity against Her2 0b reast cancer cells (MDAM B468) in the presence of PBMCs after 24 h. This nonspecific cytotoxicityw as more evident in an extended (72 h) culture with PBMCs, but was not observed with purified Tcells ( Figure 2B ). In addition, as shown in Figure 2C ,2 4h cultures treated with the IgG-based bsAbs resulted in an upregulation of T-cell activation markers (CD25 and CD69) to as imilar degree as fulllength UCHT1, whereas both trastuzumab and the Fab-based constructs did not activate Tcells.L ikewise, Tetra-IgG,T ri-IgG,a nd UCHT1 enhanced inflammatory cytokine (IL2 and TNF-a)secretion and granzyme Be xpression ( Figures 2D and  S7 ). To further confirm whether the Fc-FcR interaction is responsible for the observed nonspecific activation of Tcells,w eg enerated an Fc null version of Te tra-IgG,i nw hich two residues (L237 and L238) in the Fc domain were mutated to alanine to minimize FcR-binding. [33] Similar to BiFab,T etraIgG (Fc null) showed reduced nonspecific killing of MDA MB468 cells in comparison to Te tra-IgG (Fc intact;F igure S8). Overall, our findings demonstrate that bsAb constructs containing the CD3 binding domain and af unctional Fc domain can specifically crosslink Tcells with FcR-positive immune cells,r esulting in the activation of Tcells in an antigen-independent manner.T his observation is consistent with previous preclinical reports, [34, 35] including safety data from aclinical trial with ertumaxomab,anIgG-version bsAb with af unctional Fc domain, in which nearly all the patients developed symptoms of CRS. [36] Nonetheless,t he reduced nonspecific activity of Te tra-IgG (Fc null) suggests that am utational approach can potentially improve the safety of IgG-like bsAbs. . .
We next compared the efficacy of bsAbs with apreviously reported Her2-targeted ADC,T -nAF,i nw hich the cytotoxic drug monomethyl auristatin is site-specifically conjugated to am utant trastuzumab bearing pAcF at the heavy chain residue of A121 (35) . This homogeneous T-nAF (with adrug to antibody ratio of two) was reported to have excellent in vitro and in vivo efficacies (eradicates Her2 3 + tumors in aSCID mouse xenograft model with asingle dose of T-nAF at 5mgkg À1 ). [20, 37, 38] In 24 hcytotoxicity assays using PBMCs,TnAF elicited appreciable but lower activity compared to the bsAbs against Her2 3 + and 2 + cells ( Figures 3A and S9 , and Table S6 );t his difference in cytotoxicity increased further after 72 h( Figure S10 and Table S7 ). Of particular note,TnAF failed to lyse Her2 1 + cancer cells in 24 ha nd 72 h cultures,which is consistent with preclinical data reported for T-DM1. [5] In contrast, bsAb treatment resulted in efficient lysis of Her2 1 + cancer cells.Inorder for an ADC such as TnAF to have efficacy, the antibody/antigen complex must be internalized and the drug is released within the target cell. [39] Accordingly,w ea ssessed the internalization of T-nAF by immunofluorescent staining, and observed that T-nAF is present in Her2 3 + and 2 + cells,b ut not in Her2 1 + and 0 cells ( Figure 3B ). However,a ss hown in Figure 3C ,w e observed efficient recruitment of Tcells (green) to the target cells (red) in the presence of bsAbs (Tetra-IgG or BiFab) in all Her2 expressing cancer cells (Her2 3 + ,2+,and 1 +), but not Her2 0c ells,s upporting the increased antigen sensitivity of bsAbs over T-nAF that was observed in the cytotoxicity assays.
To determine whether the activity observed in in vitro assays translates to in vivo mouse xenograft models,w ef irst evaluated the pharmacokinetics of bsAbs by i.v.i njection into CD1 female mice.T he IgG-based bsAbs (Tetra-IgG and Tri-IgG) have similar elimination half-lives of 79.9 AE 1.6 h and 79.5 AE 0. À1 , seven doses every other day), or saline and observed for 5weeks.A s shown in Figure 4A and B, mice treated with either T-nAF or bsAbs (Tetra-IgG or BiFab) demonstrated significant inhibition of tumor growth in both the Her2 3 + and Her2 2 + groups in comparison to the control group in which mice only received Tcells and saline.Infusion of Tcells together with T-nAF did not affect the complete regression of established Her2 3 + and 2 + tumors,c onfirming our previous results. [20, 37] Next, we evaluated the same agents in Her2 1 + (MDAM B231 and MDAMB435) xenograft models.Inthese studies,the dosing regimen for T-nAF and bsAbs was the same as that described above.Inconsideration of the limited number and potentially (photons/s/cm 2 /steradian)/(mW/cm 2 ), respectively) (Figures S12 and S13). Thet umor-to-muscle ratio (TMR) of bsAbs in organs and tissues dissected at 72 hp ost injection is summarized in Figure S14 , showing that Tetra-IgG accumulation in the tumor is higher than BiFab.
Overall, the in vivo efficacys tudies verified our in vitro findings and further support the notion that bsAbs are highly effective for targeting breast cancer cells with antigens of low abundance.F urther comprehensive in vivo studies,i ncluding dose titration studies,are necessary to determine the optimal dosage of bsAbs.M oreover,f uture surrogate studies in immunocompetent mice will provide additional information regarding the efficacy and safety of bsAbs.Inconclusion, the data presented here suggest that the monovalent BiFab in the absence of an Fc domain may be the best bsAb format to trigger antigen-dependent T-cell activation and target tumor eradication for low or heterogeneous Her2 expressing cancers.
Keywords: antibody drug conjugates ·T-cell activation · bispecific antibodies ·breast cancers · noncanonical amino acids Figure 4 . In vivo efficacy comparison of T-nAF and bsAbs in human breast cancer xenograftm odels. ForHCC1954 (A) and MDA MB453 (B) xenograft studies, eight days after subcutaneous implantation of 510 6 cancer cells in 50 %Matrigel, female NSG mice received one intraperitoneal (IP) injection of 30 10 6 activatedTcells. ForMDA MB231 (C) and MDA MB435 (D) xenograft studies, seven days after subcutaneous implantation of 20 10 6 or 210 6 cancer cells in 50 % Matrigel, respectively,m ice were injected three times with 20 10 6 activated Tcells every six days via IP. Forall studies, two days after the initial T-cell infusion, mice were treated intravenously with one dose of T-nAF (5 mg kg À1 )orT etra-IgG (10 mg kg
À1
), or seven doses of BiFab (1 mg kg
)o rsaline every other day.T umors were measured twice aw eek with calipers, and tumor volume was calculated by WLH. Each data point represent mean tumor volume of five mice in each group AE SD. Arrows indicate the time of activated PBMC injections or of treatment with specified therapeutics. P values < 0.05 compared to the control groups (saline + Tcells) were considered significant.
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